Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use [Yahoo! Finance]
Insmed (INSM) had its price target raised by Barclays PLC from $231.00 to $237.00. They now have an "overweight" rating on the stock.
Drugmakers delay some European launches with a wary eye on Trump's pricing policies 1 / 2 [Yahoo! Finance Canada]
Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28% [Yahoo! Finance]
Insmed (INSM) was upgraded by Morgan Stanley from "equal weight" to "overweight". They now have a $212.00 price target on the stock.